Impact of EGFR
EGFR
glioblastoma
mutation
overlap score
radiotherapy
relapse pattern
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
12
09
2022
revised:
07
11
2022
accepted:
08
11
2022
pubmed:
26
12
2022
medline:
8
3
2023
entrez:
25
12
2022
Statut:
ppublish
Résumé
Molecular factors influence relapse patterns in glioblastoma. The hotspot mutation located at position 289 of the extracellular domain of the epidermal growth factor receptor (EGFR An ancillary study from a prospective cohort of patients suffering from glioblastoma was conducted. All patients received radiotherapy and concomitant temozolomide. The population was divided into two groups according to EGFR One hundred twenty-eight patients were included and analyzed: 11% had EGFR We highlighted a link between the EGFR
Sections du résumé
BACKGROUND
Molecular factors influence relapse patterns in glioblastoma. The hotspot mutation located at position 289 of the extracellular domain of the epidermal growth factor receptor (EGFR
PATIENTS AND METHODS
An ancillary study from a prospective cohort of patients suffering from glioblastoma was conducted. All patients received radiotherapy and concomitant temozolomide. The population was divided into two groups according to EGFR
RESULTS
One hundred twenty-eight patients were included and analyzed: 11% had EGFR
CONCLUSION
We highlighted a link between the EGFR
Identifiants
pubmed: 36566697
pii: S2059-7029(22)00374-X
doi: 10.1016/j.esmoop.2022.100740
pmc: PMC10024094
pii:
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100740Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
PLoS One. 2019 May 15;14(5):e0215838
pubmed: 31091262
Genome Res. 2015 Mar;25(3):316-27
pubmed: 25650244
Bioinformatics. 2016 Oct 1;32(19):3012-4
pubmed: 27288499
Cancer Cell. 2018 Jul 9;34(1):163-177.e7
pubmed: 29990498
J Clin Oncol. 2009 Mar 10;27(8):1275-9
pubmed: 19188675
Radiat Oncol. 2014 Jun 06;9:130
pubmed: 24906388
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
pubmed: 20399036
Acta Neuropathol Commun. 2020 Apr 17;8(1):52
pubmed: 32303258
Eur J Nucl Med Mol Imaging. 2015 May;42(6):858-67
pubmed: 25680400
Neuro Oncol. 2008 Dec;10(6):1019-24
pubmed: 18676355
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Neuro Oncol. 2022 Dec 1;24(12):2035-2062
pubmed: 36125064
Nature. 2022 Feb;602(7897):518-522
pubmed: 35140400
CNS Oncol. 2019 Mar 1;8(1):CNS28
pubmed: 30806082
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
World Neurosurg. 2018 Jan;109:e662-e668
pubmed: 29061455
Rev Neurol (Paris). 2022 Nov;178(9):975-980
pubmed: 35871016
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
BMC Cancer. 2021 Jun 22;21(1):720
pubmed: 34154559
Radiother Oncol. 2010 Dec;97(3):377-81
pubmed: 20855119
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1383-1395
pubmed: 33771703
Cancer Radiother. 2016 Sep;20 Suppl:S69-79
pubmed: 27521036
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):792-803
pubmed: 33524546
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Genome Res. 2017 Mar;27(3):491-499
pubmed: 28100584